



ASX Release

CAPITAL STRUCTURE AND RESTRICTED SECURITIES

Noxopharm Limited (ASX:NOX) ("the Company") would like to advise that set out below are a capital structure table, details of restricted (escrowed) securities and holdings of performance shares following completion of the raising of \$6,000,000 under the Offer made in the Company's Replacement Prospectus dated 24 June 2016.

Updated Capital Structure

Fully Paid Ordinary Shares:	Number	%
Pre-IPO Shares (free-trading)	3,560,000	5%
Offer (New Shares)	30,000,000	40%
Sub-total (free trading)	33,560,000	45%
Escrowed shares	41,611,429	55%
Total Shares	75,171,429	100%

Options (unlisted):	Number	Exercise Price	Expiry Date
Options (escrowed)	22,585,716	30 cents	28 February 2021
Total options	22,585,716	30 cents	28 February 2021

Performance shares (unlisted):	Number	Milestone
Performance shares (escrowed)	10,000,000	The Company obtaining a market capitalisation of \$50,000,000 by 28 February 2021
Total performance shares	10,000,000	

Noxopharm Limited
ABN 50 608 966 123

Suite 1, Level 6, 50 Queen Street, Melbourne VIC 3000
PO Box 824, Turrumurra NSW 2074
www.noxopharm.com | (02) 9144 2223

Restricted (Escrowed) Securities

Fully Paid Ordinary Shares

Number restricted	Restricted until
464,750	1 January 2017
4,261,214	1 April 2017
36,885,465	24 months from listing

Options

Number restricted	Restricted until
357,500	8 January 2017
3,277,858	1 April 2017
18,950,358	24 months from listing

Performance shares

Number restricted	Restricted until
10,000,000	24 months from listing

Performance share holdings (all restricted)

Holder	Number
Milligene Pty Ltd ^	6,877,568
DRH Superannuation Pty Ltd	1,424,808
Anglo Menda Pty Ltd	1,331,378
Helium Management Pty Ltd^^	366,246
Total	10,000,000

^ An associate of a director, Dr Graham Kelly.

^^ An associate of a director, Dr Ian Dixon.